Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
03-11
Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <nktr.oq> expected to post a loss of 17 cents a share - Earnings Preview </nktr.oq>
  • Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports results on March 12 for the period ending December 31 2024

  • The San Francisco California-based company is expected to report a 25.0% increase in revenue to $29.86 million from $23.89 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of 17 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Nektar Therapeutics is $4.00​, above​ its last closing price of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.22

-0.21

-0.18

Beat

14.6

Jun. 30 2024

-0.21

-0.20

-0.25

Missed

-22.8

Mar. 31 2024

-0.19

-0.19

-0.19

Met

0​

Dec. 31 2023

-0.22

-0.21

-0.22

Missed

-3.6

​​Sep. 30 2023

-0.21

-0.20

-0.24

Missed

-20.3

Jun. 30 2023

-0.31

-0.28

-0.27

Beat

4.9​

Mar. 31 2023

-0.23

-0.25

-0.32

Missed

-26.7

Dec. 31 2022

-0.44

-0.45

-0.32

Beat

29.3

This summary was machine generated March 10 at 20:28 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10